A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
This is an open-label, three-part study to evaluate the safety, tolerability,
pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2
expressing or mutated advanced malignant solid tumor subjects.